Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Robert Langer
Biotech
After $2.1B Novo deal, Vivtex is just getting started
Despite signing a deal potentially worth $2.1 billion, Vivtex CEO Thomas von Erlach, Ph.D., refuses to rest on his laurels.
Will Maddox
Apr 8, 2026 8:00am
Novo Nordisk inks $2.1B oral drug delivery pact
Feb 25, 2026 8:00am
Langer-backed biotech looks to end cancer recurrence
Feb 12, 2026 8:00am
RNA biotech Soufflé rises with $200M and Big Pharma partners
Oct 7, 2025 3:30pm
Biotech veteran Robert Langer joins son launching new VC
Sep 18, 2025 3:15pm
Langer spinout Lyndra begins winding down, lays off staff
Mar 27, 2025 10:58am
